HPV Vaccination in Women with Adenomyosis

Safety and Efficacy

The HPV 9 vaccine is safe to administer to a 49-year-old woman with adenomyosis who is taking medication for the condition, as the HPV vaccine is not a live vaccine and has no known drug interactions with adenomyosis medications, according to the Centers for Disease Control and Prevention (CDC) 1
The HPV vaccine was originally licensed for women aged 9-26 years, but newer data show safety and immunogenicity in older women, as reported by the Journal of Microbiology, Immunology and Infection 2, 3
The 9vHPV vaccine is safe and well-tolerated in women aged 27-45 years, with a similar safety profile to younger age groups, as stated by the Journal of Microbiology, Immunology and Infection 3, 4

The quadrivalent and 9vHPV vaccines are not live vaccines, which means they have no components that could adversely impact the safety or efficacy of other medications, as reported by the CDC 1
The HPV vaccine can be administered concurrently with other age-appropriate vaccines using a separate syringe at a different anatomic site, with no significant drug interactions, as stated by the CDC 1
There are no known contraindications to HPV vaccination related to adenomyosis or common medications used to treat it, such as hormonal therapies, NSAIDs, or GnRH agonists, as reported by the CDC and the Journal of Microbiology, Immunology and Infection 1, 3

The 9vHPV vaccine has a consistent safety profile across all age groups studied, with the most common adverse events being injection-site reactions and systemic events, which are mild and self-limited, as reported by the Journal of Microbiology, Immunology and Infection 3, 4
Vaccine-related serious adverse events are rare, and there have been no deaths attributed to the vaccine, as stated by the Journal of Microbiology, Immunology and Infection 3

The benefit of vaccination decreases with age due to the higher likelihood of previous HPV exposure, as reported by the Journal of Microbiology, Immunology and Infection 2
For women aged 27-45 years, catch-up vaccination may be considered through shared clinical decision-making, but for women aged 49, the evidence is more limited, as stated by the Journal of Microbiology, Immunology and Infection 2
Vaccination is not therapeutic for existing HPV infection or cervical lesions, so the primary benefit is protection against HPV types that have not been acquired, as reported by the CDC 1
Cervical cancer screening recommendations do not change even if vaccinated, so regular screening should be continued, as stated by the CDC 1

The 3-dose schedule is recommended for individuals who start vaccination at age 15 years or older, with dose 2 given 2 months after the first dose and dose 3 given 6 months after the first dose, as reported by the CDC and the Journal of Microbiology, Immunology and Infection 1, 3

The decision to vaccinate should be based on individual risk factors, such as sexual history, number of lifetime partners, and likelihood of future HPV exposure, as reported by the Journal of Microbiology, Immunology and Infection 2
If the patient has limited lifetime sexual partners or a new partner, the benefit of vaccination may be more significant, as stated by the Journal of Microbiology, Immunology and Infection 2
Adenomyosis and its medications should not be a barrier to vaccination if it is clinically indicated, as reported by the CDC and the Journal of Microbiology, Immunology and Infection 1, 3